Drugs / Ocedurenone
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT04634812 | Dec 2020 | — | KBP Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT04606537 | Oct → Nov 2020 | — | KBP Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT04534699 | Aug → Nov 2020 | — | KBP Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT02837237 | Jul → Dec 2016 | chronic kidney disease | KBP Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT02653014 | Jul 2015 → May 2016 | impaired renal function disease | KBP Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT02228733 | Jun 2014 → Jan 2015 | — | KBP Biosciences | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT03574363 | Apr 2018 → Aug 2020 | chronic kidney disease, hypertensive disorder | KBP Biosciences | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT04968184 | Nov 2021 → Jan 2024 | chronic kidney disease | KBP Biosciences | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03340753 Comparator | Oct → Nov 2017 | — | KBP Biosciences | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-10-16 | Novo Nordisk A/S | Novo Nordisk to acquire ocedurenone for uncontrolled hypertension from KBP Biosciences novonordisk.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ocedurenone | “Ocedurenone (KBP-5074) is a novel nonsteroidal mineralocorticoid receptor antagonist that has demonstrated safety and efficacy in clinical trials in patients with uncontrolled...” PMID 38329646 ↗ Feb 2024 |
| Known as | KBP-5074 | “Ocedurenone (KBP-5074) is a novel nonsteroidal mineralocorticoid receptor antagonist that has demonstrated safety and efficacy in clinical trials in patients with uncontrolled...” PMID 38329646 ↗ Feb 2024 |
| Action | Inhibit | “KBP-5074 mineralocorticoid receptor antagonist” NCT02837237 ↗ |
| Modality | Small molecule | — CHEMBL5314961 ↗ |
| Route | Oral | “following Oral Administration” NCT02228733 ↗ |